相关临床试验
13
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
11
84.6%
终止
2
15.4%
暂无批准数据
- Fujirebio Diagnostics has acquired all shares of Plasma Services Group, a specialized supplier of rare biological materials for in vitro diagnostics and life science research since 2004. - The acquisition strengthens Fujirebio's position as a contract development and manufacturing organization (CDMO) partner by expanding access to difficult-to-obtain biological raw materials. - Plasma Services Group operates from an FDA-registered, ISO-certified facility in New Jersey and specializes in rare disease biomarkers and sample collection services globally. - The combined companies will offer enhanced synergies in rare samples and biological materials to support scientists and innovators in the global IVD landscape.
- AriBio and Fujirebio Diagnostics have completed a significant biomarker sample collection from over 1,150 participants in the Phase 3 POLARIS-AD trial for early Alzheimer's disease. - The collection includes matched plasma and cerebrospinal fluid samples at baseline and after 52 weeks of treatment, creating one of the world's largest biobanks for this patient population. - The samples will support Fujirebio's development of blood-based biomarkers for amyloid pathology assessment, building on their pioneering work as the first company to receive FDA authorization for an Alzheimer's diagnostic test in 2022.
